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Abstract
Background: Every year many dogs in Sweden are bitten by Vipera berus, the only venomous viper in Sweden. This 
prospective study investigated clinical signs, some biochemical parameters, treatment, and progress of disease after 
snakebite in 53 dogs. Effects of treatment with and without glucocorticoids were evaluated.
Methods: All fifty-three dogs bitten by Vipera berus were examined the same day the dog was bitten and the next day. 
Two more examinations during 23 days post snake bite were included. Creatinine, creatine kinase (CK), alanine 
aminotransferase (ALT), glutamate dehydrogenase (GLDH), alkaline phosphatase (ALP) and bile acid results were 
followed through 3 to 4 samplings from 34 of the dogs.
Results: All dogs had variable severity of local swelling in the bite area and 73 per cent had affected mental status. 
Initial cardiac auscultation examination was normal in all dogs, but six dogs had cardiac abnormalities at their second 
examination, including cardiac arrhythmias and cardiac murmurs. All dogs received fluid therapy, 36 dogs were given 
analgesics, 22 dogs were treated with glucocorticoids, and ten dogs were treated with antibiotics. Evidence of transient 
muscle damage (increased CK) was seen one day after the snake bite in 15 (54%) of 28 sampled dogs. Moderate 
changes in hepatic test results occurred in 1 dog and several dogs (22 of 34) had transient, minor increases in one or 
more hepatic test result. No dog died during the observation period as a consequence of the snake bite.
Conclusions: Snake bite caused local swelling in all dogs and mental depression of short duration in most dogs. Some 
dogs had transient clinical signs that could be indicative of cardiac injury and some other had transient biochemical 
signs of liver injury. Treatment with glucocorticoids did not have any clear positive or negative effect on clinical signs 
and mortality.
Background
Every year during the period April through September
many dogs are bitten by Vipera berus, the only venomous
snake in Sweden. Vipera berus belongs to the group of
snakes called vipers. Vipers are widely distributed
throughout Europe and Asia, from western Europe
(Great Britain, Scandinavia, France) across central (Italy,
Albania, Bulgaria and northern Greece) and eastern
Europe to north of the Arctic Circle, and Russia to the
Pacific ocean, Sakhalin, Island North Korea, northern
Mongolia and northern China [1,2].
Despite the fact that Vipera berus envenomation is
common in dogs and has a reported mortality of 3.5 - 4%,
few investigations have addressed the clinical signs, bio-
chemical findings and results of treatment [1,3,4]. The
venom produced by V. berus is cytotoxic and stimulates
production of cytokines, which can result in increased
vascular permeability, vasodilatation and oedema. In seri-
ous cases the fluid loss from the capillary bed together
with vasodilatation can cause severe hypovolaemia and
distributive shock [5]. Therapeutic regimes used in Swed-
ish veterinary medicine originate mainly from treatment
recommendations in American textbooks concerning
snakes related to the Swedish viper. The treatment often
consists of a combination of intravenous fluids, glucocor-
ticoids and antibiotics. The use of glucocorticoids, how-
ever, is controversial and its value has been questioned
[4,6]. * Correspondence: jessicabergerlervik@live.se
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The main purposes of this prospective study were to
better describe the clinical signs, to summarize evidence
of organ damage based on physical exam and laboratory
testing results and to evaluate treatment effectiveness
especially with the question of use of glucocorticoids in
treatment of snake bite with the Swedish viper.
Methods
The study included dogs bitten by Vipera berus presented
at Södra Djursjukhuset in Stockholm and at the Univer-
sity Animal Hospital at the Swedish University of Agri-
cultural Sciences in Uppsala, Sweden, during the period
April through August 2006. The inclusion criteria were a
strong suspicion of viper bite at the time of presentation
based on information from the dog owner (had seen the
dog being bitten or seen a viper close to the dog) and/or
clinical signs of a viper bite such as lethargy or swelling in
the area of the suspected bite. Criteria for exclusion from
the study were ongoing treatment with glucocorticoids
for other reasons than the viper bite or a known history of
liver disease.
The case history was obtained, including signalment
(breed, age, sex, weight), time interval between the bite
and presentation, and if any glucocorticoid treatment was
given. Clinical data including mental status, body tem-
perature, cardiovascular parameters (colour of mucous
membranes, capillary refill time, heart rate/rhythm), the
localisation of the bite and the degree of swelling were
recorded. The degree of swelling was estimated by the
examining veterinarian and the grade (none, minor, mod-
erate or severe) was noted in a questioner prepared for
this study. Mental status was based on if the dog was alert
or slightly, moderately or severely depressed. Blood sam-
ples for the study were collected at presentation before
therapy was initiated. The treatment at the two hospitals
was adjusted to the patients' individual needs and was
decided by the veterinarian on duty.
The dogs were examined, and if possible blood sam-
pled, at four time points: on arrival (examination 1, 53
dogs), at 24 hours (examination 2, 52 dogs), and at follow-
up on day 4-10 (examination 3, 46 dogs) and day 9-23
(examination 4, 33 dogs) after presentation. The time
points for follow-up examinations and blood sampling
were adjusted to suit the dog owners. Serum for the study
was harvested and frozen (-20°C) until analysis at one
time point one to five months after presentation.
The dogs were hospitalised for treatment and observa-
tion. Recording of ECG was not made in all dogs as a rou-
tine but was decided by the treating veterinarian. The
duration of hospitalisation was decided based upon the
clinical progression of the patient. The time for discharge
from the clinic was decided by the treating veterinarian.
Approval of the study was obtained from the local Ethi-
cal Committee on Animal Experiments. Owner consent
was given for all dogs studied.
Serum biochemistry
In 34 of the total 53 dogs was it possible to collect serum
at three or four examinations. In the remaining 19 dogs
serum was only available from one or two time points,
and these samples were not analysed and therefore
excluded from the biochemical part of the study.
Serum concentrations of alanine aminotransferase
(ALT), alkaline phosphatase (ALP), bile acids, glutamate
dehydrogenase (GLDH), creatine kinase (CK) and creati-
nine were determined using an auto analyzer Konelab 30
(Thermo Clinical Labsystems Oy, Vantaa, Finland). Com-
mercial reagents from Termo (Thermo) were used for all
parameters, except for CK (DiaSys Diagnostics, Hot-
zheim, Germany), bile acids (Diazyme Laboratories, San
Diego, US) and GLDH (Roche Diagnostics, Mannheim,
Germany). There was no information if bile acids were
pre or post prandial.
Statistical analysis
One-way ANOVA was applied to evaluate differences in
clinical and biochemical parameters between glucocorti-
coid treated group and the not glucocorticoid treated
group (program JMP v5.0 [SAS, Cary, NC, US]). Sign
rank test of median (Minitab 15, Minitab Ltd, Coventry,
UK) was used to evaluate changes in biochemical param-
eters between the first sample within a few hours after the
snake bite and the sample after 24 hours. No basal value
was available because all four examinations were per-
formed after the snakebite. Non-parametric methods
were used because the distribution of the biochemical
parameters was not parametric. Spearman rank correla-
t i o n  ( M i n i t a b  1 5 )  w a s  u s e d  t o  e v a l u a t e  c o r r e l a t i o n
between swelling and mental status at the first examina-
tion and between swelling and CK-levels at the first two
examinations.
The dogs were grouped according to whether they had
received glucocorticoid therapy (GT) or not (NGT).
Results
Clinical findings
Of the 53 dogs, 32 were female (60%) and 21 were males
(40%). The most common breeds were German shepherd
(15%), Labrador retriever (9%), cross breed (8%), Flat
coated retriever and Golden retriever (6% each). The ages
of the dogs ranged from 3 months to 10 years, with a
mean and median age of 4 years. The mean body weight
was 25 kg (range 7 - 52 kg).
Four of the dogs were under treatment for other dis-
eases at the time of the viper bite. One dog received syn-Lervik et al. Acta Veterinaria Scandinavica 2010, 52:26
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thetic thyroid hormone and trilostan for hypothyroidism
and Cushing's disease, one dog received carprofen for
back pain, one dog was treated with cefalexin and milbe-
mycinoxim for demodicosis and atopic dermatitis and
one dog was treated for external otitis with fusidindi-
etanolamin, framycetin sulphate, nystatin and predniso-
lone. Further, one dog had a short period of lethargy and
vomiting of unknown origin prior to the bite that
resolved without treatment, and one dog had a one week
old dog bite wound in the neck that was not treated.
Seventy-four per cent of the dogs were presented to the
hospital within 3 hours of the snake bite and all dogs
within 7 hours of the bite.
In 31 of the 53 dogs the owner observed the dog being
bitten or a snake near the dog. In the remaining 22 dogs
the signs and history were strongly indicative of a snake
bite.
All dogs had a varying degree of swelling in the area of
the bite (Fig. 1). Most dogs were bitten in the head/nose
(77%). Other locations were hind limb (13%), front limb
(6%), neck and prepuce (2% each). On arrival at the hospi-
tal 73% of the dogs had an affected mental status (Fig. 2)
and seven % of the dogs had an elevated body tempera-
ture (> 39.5°C). Cardiac variables were normal on auscul-
tation in all dogs at examination 1. Spearman correlation
between degree of swelling and degree of impairment of
the mental status was low (r = 0.32).
All dogs except one were hospitalised for treatment and
observation. All dogs received fluid therapy, consisting of
crystalloid fluids (Ringer-Acetat, Fresenius Kabi, Hom-
borg, Germany; Rehydrex with Glucose 2.5%, Fresenius
Kabi, Homborg, Germany). The dosage ranged from 40-
60 ml/kg/h to 40-60 ml/kg/day depending on the findings
at the clinical examination on arrival. In some cases (28
dogs) the fluid therapy also included colloid fluids at dos-
ages ranging from 5-20 ml/kg/10 min to 0.8 ml/kg/day
(Haes-steril 60 mg/ml, Fresenius AG Bad Homburg, Ger-
many; Voluven 60 mg/ml, Fresenius AG Bad Homburg,
Germany).
Altogether 21 dogs (40%) were treated with glucocorti-
coids. Seven dogs (14%) were treated by the dog owner or
referring veterinarian before arrival (Table 1). Fifteen
dogs were treated on arrival at the hospital, two of these
dogs had also been treated by the dog owner. Thirty-one
dogs (60%) did not receive glucocorticoid treatment.
Thirty-six of the 53 dogs (68%) were treated with anal-
gesics including buprenorphine, methadone hydrochlo-
ride or transdermal fentanyl for 1-6 days. Ten of the 53
dogs (19%) were given antibiotics. Clinical signs related
to infection of the snake bite were not seen in any dog. No
dog received antiserum as part of the treatment. Sixty-
nine % of the dogs was discharged after one day of obser-
vation and treatment (range 1-6 days).
Only 16% of the dogs still had an affected mental status
and none had an elevated body temperature at examina-
tion 2. Swelling persisted around the area of the bite in all
dogs and in some cases it was more pronounced than at
the first examination (Fig. 2). Six dogs (11%) had cardiac
abnormalities at examination 2, including cardiac
arrhythmias, identified on auscultation, in five dogs (9%)
and cardiac murmurs in two dogs (4%). The five dogs
with arrhythmia were further evaluated with ECG and
the arrhythmia was classified in two of the dogs as ven-
tricular extra systoles in one dog and ventricular tachy-
cardia in the other dog. These two dogs were treated with
an anti-arrhythmic drug. Of the two dogs with cardiac
murmur one was defined as physiological murmur at
ultrasound, the other dog was not examined with ultra-
sound. Five of the six dogs with cardiac abnormalities had
received glucocorticoids.
At examination 3 (day 4-10) some degree of swelling
still remained in nine out of 35 dogs examined. At the
fourth examination (day 9-23) there was no residual
swelling in the region of the snake bite in any of the dogs
(Fig. 1). In other respects the dogs were considered clini-
Figure 1 Relative number of dogs with swelling around the area 
of the snakebite at the four examinations. Ex = examination, NGT = 
Not glucocorticoid treated, GT = Glucocorticoid treated.
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Figure 2 Mental status at the four examinations. Ex = examination, 
NGT = Not glucocorticoid treated, GT = Glucocorticoid treated.
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cally normal at the third and fourth examinations except
for one dog at the third examination, two dogs at the
fourth examination and one dog at both the third and
fourth examination, in which the mental status was still
considered to be mildly affected.
No dogs died during the observation period as a conse-
quence of the viper bite. One dog was euthanized during
the observation period due to a suspected pulmonary
neoplasia on x-ray but the diagnosis was not confirmed
with autopsy.
Differences in treatment groups
In most cases (83%) the degree of swelling was estimated
before the start of treatment with glucocorticoids. At
examination 1, the group of dogs treated with glucocorti-
coids showed a trend towards a greater degree of swelling
compared with the group of NGT dogs, however, the dif-
ference was not significant. Neither was there any differ-
ence in the degree of impairment of the mental status
between the treated and untreated group. Twenty-seven
% of the dogs in the GT group displayed increased swell-
ing at examination 2 compared with examination 1,
whereas this proportion in the NGT group was 24 per
cent. There was no significant difference between the two
groups in other clinical parameters.
In the group of dogs treated with analgesics on admis-
sion, 20 per cent still had an affected mental status the
day after arrival, in contrast to the group that did not
receive analgesics, in which the mental status was unaf-
fected in all dogs.
Biochemical results
Evidence of muscle damage, seen as serum CK above ref-
erence values, was seen in 15 of the 28 sampled dogs
(54%) at examination 2 (table 2). A pronounced increase
(>1200 U/L) was seen in seven dogs (25%) (Fig. 3). In only
three dogs did the CK values remain above the reference
value at the third and fourth examination. There was no
correlation (Spearmans correlation) between the degree
of swelling and CK values at examination 1 and 2 (r = -
0.14 and r = 0.07).
There were biochemical signs of suspected transient
hepatic injury in some dogs. Of the 34 sampled dogs 65%
had serum concentration above reference values of at
least one liver enzyme at one or more than one examina-
tion (Table 1, Fig. 4, Fig. 5).
Of these 34 dogs, 22 were not treated with glucocorti-
coids. In this NGT group, one dog had biochemical
changes that strongly indicated liver damage, with a mod-
erate increase in ALT, GLDH and ALP at examinations 3
and 4 (Fig. 4, Fig. 5). One other dog had results above ref-
erence values in GLDH and bile acids at examination 3
without any change in other parameters. Two further
dogs had a slight increase in ALP at different time points
without any increase in other liver parameters. There was
a l s o  o n e  d o g  w i t h  o n l y  a  s l i g h t  i n c r e a s e  i n  G L D H  a t
examination 1 and another dog with a high ALT value at
examination 4.
Of the 34 dogs, 12 were treated with glucocorticoids
and in this group a minor, but significant, increase in ALP
was seen between examinations 1 and 2 (p < 0.05, sign.
test) (Fig. 4). Four individuals had results slightly above
reference values in GLDH (Fig. 5) and ALT at one or two
examinations. In one dog GLDH and ALT were already
elevated at presentation ( examination 1). This dog had
been treated with glucocorticoids by the owner two hours
before arrival at the hospital. ALT was significantly
higher (p < 0.05, ANOVA) in the glucocorticoid treated
Table 1: Treatment with glucocorticoids pre or at admittance
No dogs(%) Number of
treatments
Dosage
No treatment 31 (60%) - - -
Pre admittance 5 (10%) betamethasone p.o.1 Once 0,1-0,25 mg/kg
1 (2%) prednisolone inj2 Once 0,6 mg/kg
1 (2%) prednislone p.o3 Once 1 mg/kg
At admittance 11 (21%) prednisolone inj2 Once 1-2 mg/kg
2 (4%) prednisolone inj2 2 -5 days 0,2-2 mg/kg
3 (6%) prednisolon p.o3 Once 1-1,25 mg/kg
Two of the dogs treated at admittance had earlier been treated by the dog owner.
1 betamethasone (Betapred™ 0.5 mg, tablets, Swedish Orphan, Stockholm, Sweden)
2 prednisolone acetat (Prednisolonacetat Vet. 10 mg/ml, injection, Intervet, Danderyd, Sweden)
3 prednisolone (Prednisolon Pfizer, 2,5 mg, 5 mg, 10 mg, tablets, Pfizer AB, Sollentuna, Sweden)L
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Table 2: Biochemical parameters at examinations 1 to 4 (Ex 1-Ex 4) for both groups.
Untreated group The glucocorticoid treated group
Ex 1 Ex 2 Ex 3 Ex 4 Ex 1 Ex 2 Ex 3 Ex 4
CK N = 19 N = 18 N = 22 N = 15 N = 11 N = 10 N = 11 N = 12
Median 114 282 102 78 96 306 90 66
Range (48-258) (78-2280) (48-714) (36-330) (54-3162) (66-4524) (42-222) (42-222)
No. of dogs > reference value
(240 U/L)
1 1 0 32 3 500
GLDH N = 19 N = 18 N = 22 N = 15 N = 11 N = 10 N = 11 N = 12
Median 1980 2340 2160 2700 1680 1980 2040 1860
Range (900-5520) (1200-5880) (660-41280) (1260-4500) (6600-12600) (1380-6300) (6900-8100) (1500-8160)
No. of dogs > reference value
(4500 U/L)
1131 1 122
ALT N = 19 N = 18 N = 22 N = 15 N = 11 N = 10 N = 11 N = 12
Median 30 36 30 42 48 51 48 39
Range (6-66) (12-84) (6-276) (12-84) (30-108) (30-78) (30-120) (24-348)
No. of dogs > reference value
(72 μkat/L)
0133 1 122
ALP N = 17 N = 18 N = 22 N = 15 N = 11 N = 10 N = 11 N = 12
Median 78 93 93 96 78 210 210 153
Range (24-378) (54-366) (24-1572) (24-732) (36-168) (90-456) (90-450) (66-420)
No. of dogs > reference value
(300 U/L)
1243 0 221
Bile acid N = 18 N = 18 N = 22 N = 15 N = 11 N = 10 N = 11 N = 12
Median 1.3 1.2 2.2 3.4 2.4 1.15 3.2 3.2
Range (0.5-20.5) (0.3-17.5) (0.4-33.8) (0.8-21.2) (0.5-31.6) (0.7-8) (0.7-13.7) (0.9-29.2)
No. of dogs > reference value
(30 mmol/L)
0010 1 000
Creatinine N = 18 N = 18 N = 22 N = 15 N = 11 N = 10 N = 11 N = 12
Median 81 72 81 86 89 70.5 89 85.5
Range (67-99) (35-116) (30-102) (45-104) (49-112) (48-121) (48-103) (47-95)
No. of dogs > reference value
(130 mmol/L)
0000 0 000
The first four columns show the results from the group that was not treated with glucocorticoids (untreated). Ex = examinationLervik et al. Acta Veterinaria Scandinavica 2010, 52:26
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Figure 3 CK values at the four examinations. a) 22 dogs not treated with glucocorticoids (NGT = Not glucocorticoid treated) b) 12 dogs treated 
with glucocorticoids (GT = Glucocorticoid treated). Dog GT9 had CK concentrations of 3162 U/L at examination 1 and 4524 at examination 2. Refer-
ence value 240 U/L.
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Figure 5 GLDH values at the four examinations. 22 dogs not treated with glucocorticoids (NGT = Not glucocorticoid treated), 12 dogs treated with 
glucocorticoids (GT = Glucocorticoid treated). Dog NGT2 had GLDH concentrations of 41280 U/L at examination 3. Reference value 4500 U/L.
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group than in the untreated group at the first sampling.
No other differences in liver enzymes levels between the
two groups were seen at any time point.
Serum creatinine was within reference values for all
dogs at all examinations, except one dog that had slightly
low creatinine values at examination 2 and 3. However,
creatinine decreased from examination 1 to examination
2 in 82% of the sampled dogs (p < 0,05 Sign test).
Discussion
At the first examination within a few hours after the
snake bite all dogs had local swelling at the site of the bite
and many had an affected mental status. After 24 hours
the swelling persisted in all cases to some extent and had
increased in a few cases. However by this point most dogs
had shown clinical resolution of most other signs. How-
ever, some dogs showed transient signs that could be an
indication of organ injury, affecting heart and liver. Car-
diac arrhythmias developed in four dogs between exami-
nations 1 and 2. No abnormalities were found at
auscultation at examinations 3 and 4, and thus in our
study there was no clinical evidence of permanent myo-
cardial damage, although there was no biochemical tests
run to evaluate this.
Clinical case observations had earlier suggested that
dogs could develop hepatic disease after snake bites [1].
However, results of 4 different liver tests (ALT, ALP,
GLDH and bile acids) analyzed at four time points after
snake bite, spanning a period of 9-23 days, were inconsis-
tently and often not greatly abnormal. Only one dog had
biochemical evidence of hepatic injury, including both
hepatocellular enzyme leakage and cholestasis. Many
dogs had serum hepatic enzyme activities of one or more
than one enzyme at one or more than one examination
but these were only slightly above reference values. Mild
inconstant increases in test values must be interpreted
with caution. Reference values are based of the results
from 95% of healthy dogs, so for each sampling 5% for
each parameter are expected to be outside reference val-
ues. Thus 1/20 abnormal results may be high only by
chance. Results however suggest occasional hepatic
injury in some dogs and may be subclinical in more cases.
The changes occurred both early (within 24 hours) and
later at the third and fourth re-examination. In most
cases the increase was temporary and only one or two
parameters were affected. Hepatic injury may be from
direct cytotoxic effects of snake venom or indirectly as a
consequence of vascular damage and ischemia. In a study
by Karlsson-Stiber C, Persson H, Heath A, et al mildly
elevated values in ALT was seen in humans a few days fol-
lowing Vipera berus envenomation [7].
Glucocorticoids alone induce an increase in hepatic
enzyme activity in dogs. In experimental studies it was
found that dogs treated with 4 mg/kg dexamethasone
showed a significant increase in ALP and ALT 48 hours
after administration [8,9], whereas in a study by Peta et al.
GLDH did not increase in most dogs receiving short-
term prednisolone [10]. In the glucocorticoid treated
group in our study there was a small, however significant,
increase in ALP from sampling at occasion 1 to 2. This
increase was probably induced by glucocorticoids, as it
was not seen in the untreated group.
The elevated CK values at examination 2 were probably
caused by local muscle damage at the site of the snake
bite [11]. No evidence of renal failure was seen, however,
the serum creatinine values decreased from examination
1 to examination 2 in 82% of the blood sampled dogs. The
mild decrease might be explained by increased glomeru-
lar filtration caused by fluid therapy [12].
The biochemical changes in our study are consistent
with those reported by other authors. Aroch and Harrus
found generally mild biochemical changes in 109 dogs
poisoned by Vipera xanthina palestinae, except for signif-
icant increases in CK and GLDH [3].
The sex distribution - 32 bitches and 21 males - is simi-
lar to that reported from other studies [1,3]. The most
common breeds - German shepherd and Labrador
retriever - reflect the dog population in Sweden [13]. A
possible explanation for the age distribution (60% ≤ 4
years) may be that younger dogs are more curious and
less careful than older dogs.
The most common location of the snakebite in the head
and nose was similar to that previously reported in other
studies concerning Vipera palestinae envenomation [3,4].
In the study by Segev et al., comprising 327 dogs bitten by
V. palestinae, it was shown that the risk of mortality was
increased when the bite was located in an extremity [6].
In our study there was no correlation between the site of
the bite and the degree of affected mental status and no
deaths occurred.
The use of glucocorticoids in viper bites is controversial
and several authors have expressed doubts on the effect
of this treatment [3,14,15]. The viper's venom contains
enzymes that induce the production of endogenous
cytokines and inflammatory mediators [1]. Glucocorti-
coids have an anti-inflammatory effect, inhibit capillary
dilatation and prevent the release of vasoactive amines
[16]. Experimental studies in dogs with septic shock have
shown beneficial effects of treatment with glucocorti-
coids, but the results have been less convincing in human
clinical trials, except in a subpopulation of human
patients with relative adrenal insufficiency [17-20]. In a
retrospective study including 327 dogs bitten by V. pales-
tinae an increased mortality was found in dogs treated
with glucocorticoids [6]. The authors pointed out that it
could not be ruled out that it was the dogs with the most
severe symptoms that were treated with glucocorticoids,
and that this might have explained the increased mortal-Lervik et al. Acta Veterinaria Scandinavica 2010, 52:26
http://www.actavetscand.com/content/52/1/26
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ity. In the present study there were no significant differ-
ences between the GT and NGT groups regarding clinical
signs such as mental status, recovery period, or degree of
local swelling. However, a slight trend towards a higher
degree of swelling in the GT group than in the NGT
group was noted. A possible reason for this could be that
the severity of the clinical signs at presentation, including
the degree of swelling, may have guided the veterinarians
in their choice of treatment, so that dogs with a higher
degree of swelling were more likely to receive glucocorti-
coids.
Of the dogs treated with analgesics on admission, 20
per cent still had an affected mental status on the day
after arrival compared to those not treated with analge-
sics in all of which the mental status was considered to be
unaffected. Again an explanation for this finding might
be that the degree of affected mental status at presenta-
tion could have influenced the decision to administer
analgesics. A sedative effect of the opioids provided can
be another possible reason for the difference in mental
status between the two groups. In the present study, no
evaluation of pain was made.
The incidence of infection secondary to bites of Vipera
berus in Swedish dogs is unknown and the benefit from
antimicrobial therapy is debated. It has been reported
that despite heavy oral and fang contamination of crotalid
species with a wide variety of potentially pathogenic bac-
teria, crotalid envenomation in humans is associated with
a low incidence of bacterial infection [21]. Our study also
indicated that no clinical signs of infection were found in
any dog despite that only 19% was treated with antibiot-
ics.
No dog in the present study was treated with antise-
rum. Treatment with antiserum is the only way to inacti-
vate the enzymes in the venom, by binding them to
antibodies in the antiserum [19]. Antiserum should be
considered in severely affected dogs in which supportive
therapy is unsatisfactory [3,15,22,23]. In humans, the
treatment has been shown to be effective for up to 18
hours after the bite (Internal document from the poison
information centre in Sweden). Despite the fact that anti-
serum therapy was not used in the present study no mor-
tality occurred. Further investigations of the effects of
antiserum treatment in dogs bitten by V. berus are war-
ranted.
The mortality reported in association with viper bites
in dogs is similar in different studies. Kängström reported
a mortality rate of 3.5 per cent in a retrospective study of
170 Swedish dogs bitten by V. berus [1], and Aroch and
Harrus reported 3.7 per cent mortality in a retrospective
study of 109 dogs poisoned by V. xanthina palestinae [3].
Segev et al. reported a mortality of 4 per cent in 327 dogs
poisoned by V. xanthina palestinae [ 6].  Da ta  fr om  t he
largest animal insurance company in Sweden (Agria)
showed a mortality of 2.9 per cent in 103 reported cases
of viper envenomation in 2006 (Personal communica-
tion). This data does not include any information about
treatment surrounding the snake bite. In our study there
were no fatalities during the observation period as a con-
sequence of the viper bite.
Conclusions
In conclusion, the dogs in this study bitten by Vipera
berus recovered from initial depression within 24 hours,
whereas local swelling persisted for a longer period of
time. Other clinical signs were mild and no deaths
occurred during the follow-up period. Transient signs of
liver injury and cardiac abnormalities were found in some
dogs. It was difficult to draw any conclusions as to
whether treatment with glucocorticoids had any signifi-
cant effects on clinical signs and mortality.
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